Aclaris Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Aclaris Therapeutics, Inc. (ACRS) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period of 106.20 thousand shares for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod · last filed 2018-11-06
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2018-09-30 was 18.84K shares.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2018-06-30 was 84.21K shares.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2018-03-31 was 3.15K shares.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2015-12-31 was 399.76K shares.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2015 was 759.54K shares, a 58.33% increase from fiscal 2014.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2014 was 479.71K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month |
|---|---|---|---|---|
| 2018-09-30 | 18.84K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | 103.05K shares derived: sum of 2 quarters · filed 2018-11-06 | 106.20K shares 10-Q · filed 2018-11-06 | |
| 2018-06-30 | 84.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | 87.36K shares 10-Q · filed 2018-08-03 | ||
| 2018-03-31 | 3.15K shares 10-Q · filed 2018-05-08 | |||
| 2017-09-30 | 9.30K shares 10-Q · filed 2017-11-07 | |||
| 2015-12-31 | 399.76K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | 759.54K shares 10-K · filed 2016-03-23 | ||
| 2015-09-30 | 359.78K shares 10-Q · filed 2015-12-03 | |||
| 2014-12-31 | 479.71K shares 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |